The UK genomics sector has released a report detailing the strength of research in this area, highlighting what it sees as a broad range of investment opportunities. 30 July 2021
The Russian government, together with some leading local drugmakers, is considering investing more than 26 billion roubles ($351 million) to establish production of active pharmaceutical ingredients (APIs) within the territory of Russia until 2030, according to recent statements by representatives of some senior state officials and some local media, The Pharma Letter’s local correspondent reports. 27 July 2021
The US Association for Accessible Medicines (AAM) last week released a white paper, “New Generics Are Less Available in Medicare Than Commercial Plans.” 26 July 2021
National Health Service (NHS) patients in England are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million ($925 million) of ringfenced funding, the NHS chief executive has announced today. 21 July 2021
In anticipation of the third wave of the pandemic, the Russian government has significantly increased purchases of anti-COVID-19 drugs, according to recent statements by state press-service and local media reports. 20 July 2021
On Friday, US President Joe Biden issued a wide ranging Executive Order seeking to address overconcentration, monopolization, and unfair competition in the US economy. 13 July 2021
Troubled drugmaker Purdue Pharma has stepped a little closer to emerging from bankruptcy, after securing the backing of 15 states for a settlement related to claims arising from the ongoing opioid crisis. 9 July 2021
Biosimilar competition has the potential to provide greater access to important treatments for America’s patients and cost savings for the nation’s health care system of as much as $130 billion by 2025, notes the Biosimilars Council, a division of the USA’s Association for Accessible Medicines (AAM). 7 July 2021
The new UK Life Sciences Vision for the next 10 years has been published, promising to build on the successes of the COVID-19 response and accelerate delivery of innovations to patients. 7 July 2021
In an exceptional measure, India’s pricing regulator the National Pharmaceutical Pricing Authority (NPPA) has allowed a one-time price hike of 50% for three key drugs - ranitidine (antacid), ibuprofen (analgesic), and carbamazepine (epilepsy). 7 July 2021
Sweden-headquartered contract development and manufacturing organization (CDMO) Recipharm has signed a Memorandum of Understanding (MoU), along with His Majesty the King of Morocco, Mohammed VI, the Moroccan government and a consortium of the country’s leading banks, that will see the company operate a new fill finish factory in Morocco. 6 July 2021
The Russian Ministry of Health wants to sign long-term contracts with global drugmakers on supplies of their drugs against HIV, hepatitis and rare diseases for state needs. As part of state plans, that will allow the achievement of significant savings during public procurements of these drugs, reports The Pharma Letter’s local correspondent. 6 July 2021
The UK government’s Vaccines Taskforce (VTF) was primarily established to ensure that the UK population would have access to a clinically safe and effective vaccine against COVID-19. 6 July 2021
The Indian subsidiary of Anglo-Swedish pharma major AstraZeneca has filed a writ petition before the Delhi High Court challenging a demand notice from India's National Pharmaceutical Pricing Authority (NPPA) alleging overcharging of Tagrisso (osimertinib) tablets by the company. 1 July 2021
The Alzheimer’s community, together with the share price of USA-based developer Biogen (Nasdaq: BIIB), was given a considerable fillip at the start of June, with the approval of Aduhelm (aducanumab). 28 June 2021
Prices for imported pharmaceutical substances are steadily increasing in Russia, which creates serious problems for domestic drugmakers, whose costs have also grown significantly in recent months, according to a recent study, conducted by a local analytics company RNC Pharma, reports The Pharma Letter’s local correspondent. 22 June 2021
Cambridge, UK-based drugmaker AstraZeneca has welcomed a ruling by the Court of First Instance, in Brussels, which appeared to vindicate the company’s approach to the distribution of its coronavirus vaccine. 18 June 2021
The US government has announced it will invest more than $3 billion to boost discovery and development of new antiviral medicines for the novel coronavirus. 18 June 2021
In a move that will help ensure sub-standard or counterfeit drugs do not reach customers, India's Health Ministry is looking to make it mandatory for companies to include codes to track-and-trace key ingredients used to make medicines in India. 17 June 2021
The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
The Danish government is to remove the rules that currently prohibit the purchase of medicines from countries outside the European Union (EU) in a move that has not been welcomed by pharma. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Global leaders have approved a political declaration at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). 30 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
US biotech Emergent BioSolutions revealed it has secured approximately $400 million in orders in 2024 and 2025 associated with its vaccinia, smallpox and mpox product portfolio. 26 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
President Biden has said the USA will commit at least $500 million to support African countries in battling the ongoing mpox outbreak in Central and Eastern Africa. 25 September 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
The Foundation for Economic and Industrial Research and Greek pharma trade group the Hellenic Association of Pharmaceutical Companies have presented two studies reflecting the industry’s importance. 23 September 2024
Basilea Pharmaceutica announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) has awarded Basilea an Other Transaction Agreement (OTA), under OTA number 75A50124C00033. 20 September 2024
Novo Nordisk is under increasing pressure over the cost of its blockbuster drugs in the USA, as chief executive Lars Fruergaard Jørgensen prepares to testify before a powerful Senate committee. 18 September 2024
The research based pharmaceutical industry has welcomed Mario Draghi’s report, published by the European Commission, outlining proposals on how Europe can regain its competitive edge and the critical role of innovative industries in achieving this. 11 September 2024
Even as emerging signs of a thaw in the broader Indian start-up funding landscape were evident, the Competition Commission of India (CCI) has tightened its exemption list under new combination rules. 11 September 2024
The US House of Representatives has passed the BIOSECURE Act, gaining bipartisan support with a vote of 306–81. Nearly all of the votes against the bill came from Democrats. 10 September 2024
The Cell and Gene Therapy Catapult (CGT Catapult) has highlighted what it regards as the UK's potential to lead the global cell and gene therapy sector. 5 September 2024
The budget on October 30 is an opportunity to end short-termism, cut waste, and attract long-term investment to the country’s economy with a sector-targeted R&D tax relief policy, according to the UK BioIndustry Association (BIA). 3 September 2024
The Danish Pharmaceutical Industry Association, Lif, has given its verdict on the government financial bill setting out new priorities in health in 2025. 2 September 2024
Marseille-based ImCheck Therapeutics has received 20.2 million euros ($22.4 million) in non-dilutive funding as part of the i-Démo call for projects under the France 2030 Plan operated by Bpifrance on behalf of the French government. 29 August 2024